¿ Adenosine Therapeutics LLC, of Charlottesville, Va., in-licensed approximately 50 new A2B adenosine receptor antagonist compounds from the University of Virginia Patent Foundation and the National Institutes of Health. Disease targets include asthma, diabetes and retinopathy.
¿ BioAlliance Pharma, of Paris, raised EUR7 million (US$6.7 million) from a group of European investors that includes 3i, Capricorn Ventures, Technolife 2010, SPEF, and ABN AMRO. The company's Transdrug technology is designed to overcome drug resistance and/or achieve oral delivery of existing drugs.
¿ Connetics Corp., of Palo Alto, Calif., presented animal data on relaxin at the Wound Healing Society 2000 meeting in Toronto. The data suggest that the product could be an effective treatment for non-healing ulcers by helping improve blood flow to oxygen-deprived tissue. Relaxin is a naturally occurring human hormone with antifibrotic, angiogenic and vasodilatory properties. The product is in a pivotal trial for scleroderma, with data slated to be released this fall.
¿ Cypress Bioscience Inc., of San Diego, and Fresenius Medical Care North America have launched a program designed to bring the Prosorba Column immunoadsorption apheresis device for treating rheumatoid arthritis to doctor's offices. The device has heretofore been used in outpatient hospital settings due to personnel and equipment requirements. The new program will provide equipment and nursing support, as well as management support to assist practices with associated billing. Fresenius AG, of Bad Homburg, Germany, is the marketing partner for Prosorba.
¿ Energy BioSystems Corp., of The Woodlands, Texas, changed its name to Enchira Biotechnology Corp. The change reflects the company's move to apply its directed evolution technology to broader markets, including pharmaceutical, agricultural, chemical and industrial enzyme applications. The ticker symbol will remain ENBC.
¿ Hemispherx Biopharma Inc., of Philadelphia, said a federal court ruled it does not have jurisdiction in the defamation case that Hemispherx brought against Asensio & Company Inc., of New York.
¿ Immune Network Research Ltd., of Vancouver, British Columbia, filed a preliminary prospectus with provincial securities commissions for a special warrants private placement that closed on March 9 and raised $8.5 million (US$5.8 million.)
¿ Ivax Corp., of Miami, won approval of its chlorofluorocarbon-free beclomethasone product in Japan. Taisho Pharmaceutical Co. Ltd., of Tokyo, will market the anti-asthmatic drug in its home country.
¿ Ligand Pharmaceuticals Inc., of San Diego, received $7.7 million from the exercise of warrants to purchase shares of common stock. The warrants, which allowed for the purchase of common shares at $7.12 each, expired on June 3. Approximately 98 percent of the 1.1 million warrants outstanding as of April 30 were redeemed. Ligand shares (NASDAQ:LGND) closed Thursday at $11.625, down 7 percent.
¿ Micrologix Biotech Inc., of Vancouver, British Columbia, in-licensed an antimicrobial peptide technology devised by a team of scientists at the Harbor-UCLA Research and Education Institute in Torrance, Calif. Harbor-UCLA researcher Michael Yeaman and his research team have developed a technique for designing peptides that capture the antimicrobial activity and other essential pharmacologic properties of a special class of proteins produced by platelet cells.
¿ NaPro BioTherapeutics Inc., of Boulder, Colo., expanded its development and marketing relationship for paclitaxel with F.H. Faulding & Co. Ltd., of Underdale, Australia, to include all of Central America, South America and Mexico, as well as South Africa and some additional territories in Southeast Asia and the Middle East. Faulding first launched NaPro paclitaxel in Australia under the trade name Anzatax in January 1995.
¿ Nexell Therapeutics Inc., of Irvine, Calif., converted a non-exclusive licensing agreement with Diaclone SA, of Besancon, France, to an exclusive deal for six monoclonal antibodies for use in ex vivo cell therapy. The portfolio comprises CD138, useful for purging myeloma cells; CD25, a T-cell activation marker that may facilitate removal of alloreactive cells (thought to be responsible for graft vs. host disease) from a stem cell graft prior to transplant; CD56 and CD16, markers for natural killer cells; CD14, a monocyte marker; and CD4, the marker for T-helper cells. Nexell also gained the right of first refusal for potential in vivo applications of the antibodies.
¿ Origen Therapeutics Inc., of Burlingame, Calif., and Embrex Inc., of Research Triangle Park, N.C., are combining Origen's avian embryonic stem cell technology with Embrex's in ovo technology to improve poultry production and chick quality.
¿ Tripos Inc., of St. Louis, received a two-year Small Business Innovation Research grant of $750,000 from the National Institute of General Medical Sciences at the National Institutes of Health. The company will use the money to advance development of software to improve high-throughput screening and combinatorial chemistry.